MedTrace Logo

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

NCT02878278 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-08-25

No results posted yet for this study

Summary

1. To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect way of Chidamide administration.
2. To examine whether Chidamide could activate EB virus, and whether the above two different ways of administration are different in EB virus activation.

Conditions

  • Lymphoma, Extranodal NK-T-Cell
  • EBV

Interventions

DRUG

Chidamide BIW

Chidamide is given 30mg, twice a week

DRUG

Chidamide QD

Chidamide is given 10mg,QD

Sponsors & Collaborators

  • Huiqiang Huang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-03-31
Completion
2019-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878278 on ClinicalTrials.gov